Synthetic prosthesis comprising a knit and a non porous film and method for forming same

Information

  • Patent Grant
  • 11826242
  • Patent Number
    11,826,242
  • Date Filed
    Friday, April 3, 2020
    4 years ago
  • Date Issued
    Tuesday, November 28, 2023
    5 months ago
Abstract
The present invention relates to a synthetic prosthesis for tissue reinforcement comprising: a porous knit made from a monofilament of a synthetic biocompatible material, said knit defining two opposite faces, a first face and a second face,a synthetic non porous biodegradable film comprising at least a copolymer of at least ε-caprolactone, said film covering at least part of said first face,a synthetic biodegradable binder bonding said film to said first face, said binder comprising at least a polymer of ε-caprolactone, wherein said second face of said porous knit is left open to cell colonization.The invention also relates to a method for forming such a prosthesis.
Description
TECHNICAL FIELD

The present invention relates to a synthetic prosthesis for tissue reinforcement, the prosthesis comprising a porous knit and a biodegradable adhesion barrier film provided on one face of said knit. The prosthesis of the invention is particularly intended for the reinforcement of soft tissue where a weakness exists such as the primary abdominal wall and incisional hernias.


BACKGROUND OF RELATED ART

Reinforcement prostheses, for example prostheses for reinforcing the abdominal wall, are widely used in the surgical field. These prostheses are intended to treat hernias by temporarily or permanently filling a tissue defect. These prostheses are generally made of biocompatible prosthetic fabric, for example knits, and can have a number of shapes, for example rectangular, circular or oval, depending on the anatomical structure to which they are to be fitted.


Prosthetic fabrics such as knits are intrinsically adhesiogenic and fibrogenic, irrespective of the nature of the tissues with which they are put in contact. It is desirable to provide reinforcement prostheses that, although based on prosthetic fabric, also prevent post-surgical adhesions, especially when they are positioned intraperitoneally.


Postsurgical adhesions include all non-anatomical fibrous connections accidentally induced by a surgical act during the normal process of cicatrization. They may occur in all surgical disciplines regardless of the operation in question. Postsurgical adhesions can provoke syndromes which can be classed principally as chronic pain, occlusive syndromes and female infertility. Furthermore, they increase very substantially the risks of making errors in follow-up surgery, while prolonging the operating times, since the preliminary dissection can be very awkward in such cases.


To remedy this problem, it was suggested to render one face of these reinforcement prostheses completely smooth during the initial inflammatory phase, and therefore not favorable to the generation of adhesions. To do this, a physical barrier is interposed between the structures which are not intended to adhere to each other.


However, the desired barrier effect poses the problem of the intrinsic adhesive power of this barrier. The reason is that if the barrier is made of a non biodegradable material, it can itself be the source of adhesions over the course of time; and if it is biodegradable, its biodegradation must be sufficiently noninflammatory so as not to cause adhesions itself on one hand, and on the other hand, its biodegradation kinetics should be appropriate so as to allow the barrier to remain integrate during the time needed for it to perform its function of prevention of formation of adhesions.


SUMMARY

In the present application, the term “biodegradable” is defined to include both bioabsorbable and bioresorbable materials. By biodegradable, it is meant that the materials decompose, or lose structural integrity under body conditions (e.g., enzymatic degradation or hydrolysis) or are broken down (physically or chemically) under physiologic conditions in the body such that the degradation products are excretable or absorbable by the body.


In the present application, the term “non biodegradable” is defined to include both non bioabsorbable and non bioresorbable materials. By non biodegradable, it is meant that the materials do not decompose under body conditions and remain permanently in the body.


Adhesion barrier films are known, that are obtained via gelling of a starting solution comprising collagen. The collagen may be derived from animal or human sources. Anyway, prosthesis involving animal human derived biological materials are not always reproducible or compatible.


Moreover, it was found that the films of the prior art used as a barrier for the prevention of post-surgical adhesions may lack mechanical strength and resistance, and may delaminate once implanted. The film therefore separates from the prosthetic fabric within the body of the patient and can not perform its adhesion barrier function.


There is therefore a need for a prosthesis that would be entirely synthetic and that would comprise a fully biodegradable adhesion barrier film, said film being nevertheless resistant to delamination at least for the time necessary for it to prevent occurrence of adhesions, namely for at least 1 to 2 weeks.


In addition, in order to minimize the trauma subsequent to any surgical intervention, patients are increasingly operated by laparoscopy when the type of intervention performed allows this. Laparoscopy requires only very small incisions through which a trocar is passed, with the prosthesis being conveyed inside the trocar to the implantation site. Open surgery is thus avoided, and the patient can soon leave hospital. Laparoscopy is particularly popular in surgical interventions performed in the abdomen, for example the treatment of hernias.


However, the trocars used in laparoscopic surgery generally have a relatively small calibrated diameter, which may vary, for example, from 5 to 15 mm, in order to reduce as much as possible the size of the incision that is made. The prosthesis therefore has to be conveyed to the implantation site within a conduit of small diameter. The prosthesis is generally rolled up on itself in order to make it slide in the conduit of the trocar or is introduced directly by force, if appropriate with the aid of laparoscopy forceps.


There is therefore still the need for a prosthesis based on a knit provided with a biodegradable adhesion barrier film on one of its faces, that is soft enough to be pliable and to be foldable so that it can be easily introduced into a conduit such as that of a trocar of small diameter, without damaging the knit and the film.


Moreover, reinforcement prostheses are all the more effective and their local tolerance is all the better, the earlier and the more intimate their tissue integration. For this reason, the most effective of the known prosthetic fabrics for these indications are generally porous and are designed in such a way as to be integrated in the body as rapidly as possible.


In the present application, the term “porous” is intended to signify the characteristic according to which the faces and the thickness of the textile it refers to, such as a fabric or a knit, present pores, voids, alveoli, distributed regularly or irregularly, and promoting all cell colonization, on the surface and within/through the thickness of the textile.


In the present application, the term «non-porous» is intended to signify that the structure it refers to, such as a film, presents a smooth and even surface devoid of any pores, such a surface preventing the occurrence of postsurgical adhesions.


Moreover, in a view of reducing the foreign material implanted into the body of a patient, it is desired to produce lightweight reinforcement prostheses. In addition, for facilitating the work of the surgeon at the time he puts the prosthesis in place at the implantation site, it is further desired that the prosthesis show a good transparency. Lightweight knits showing a plurality of pores, and preferably large pores, are therefore desirable for forming lightweight reinforcement prostheses favoring a good tissue ingrowth.


There is therefore a need for a synthetic prosthesis that could be used for tissue reinforcement, for example for the reinforcement of soft tissue where a weakness exists such as the primary abdominal wall and incisional hernias, in an intraperitoneal position, possibly by laparoscopy, that would offer cell recolonization and tissue integration properties on one of its faces, while being provided on its other face with a biodegradable adhesion barrier film preventing or at least minimizing postsurgical adhesions, at least during the 4 weeks following surgery, said film being not subject to delamination. The synthetic prosthesis should also preferably minimize the amount of foreign material implanted in the body of the patient.


A first aspect of the invention is a synthetic prosthesis for tissue reinforcement comprising:

    • a porous knit made from a monofilament of synthetic biocompatible material, said knit defining two opposite faces, a first face and a second face,
    • a synthetic non porous biodegradable film comprising at least a copolymer of at least ε-caprolactone, said film covering at least part of said first face,
    • a synthetic biodegradable binder bonding said film to said first face, said binder comprising at least a polymer of ε-caprolactone,


wherein said binder is present between said film and said first face under the form of a discontinuous layer, and


wherein said second face of said porous knit is left open to cell colonization.


The prosthesis of the invention comprises two faces which are different in their respective appearances and functions, namely one face which is porous or open on one side, in order to accommodate and direct the postsurgical cell colonization, and the other face which is closed, for tissue separation without adhesion at least during the time post-surgical adhesions are likely to occur.


The prosthesis of the invention allows therefore cell colonization and tissue integration to take place on one hand, via the second face of the porous knit, while minimizing the development of adhesions on its opposite face, namely the first face of the knit which is covered by the non porous biodegradable film acting as an adhesion barrier film for at least 1 to 2 weeks.


The film is intimately linked to the first face of the knit by the binder, and cannot be delaminated, while at the same time maintaining the porosity open on the second surface of the knit.


Moreover, the cooperation of the knit, the film and the binder of the prosthesis of the invention makes it possible for tissue colonization to develop immediately, independently of complete degradation of the biodegradable film, which itself is relatively rapid, for example occurring in about 4 to 15 weeks without compromising the performance of the prosthesis. In addition, the structure of the binder, which is present under the form of a discontinuous layer of material, allows the cell colonization and tissue integration to further develop on the first face of the porous knit when the non porous film begins biodegrade after a few weeks, at a time when post-surgical adhesions are no more likely to occur and the non porous film has completed its function of prevention of adhesions.


The prosthesis of the invention is formed of synthetic materials only. Synthetic materials have the advantage of being reproducible and their behavior is well known.


In addition, the presence of a common chemical component, such as ε-polycaprolactone, both in the non porous film and in the binder of the prosthesis of the invention allows reducing the number of foreign materials of different compositions that are implanted in the body of the patient.


The prosthesis of the invention is particularly adapted to the reinforcement of abdominal wall soft tissue where a weakness exists in procedures involving primary and incisional abdominal wall hernia surgeries.


The prosthesis of the invention comprises a porous knit made from a monofilament of a synthetic biocompatible material, said knit defining two opposite faces, a first face and a second face.


The knit of the invention is made from a monofilament of a synthetic biocompatible material.


The synthetic biocompatible material may be biodegradable, non-biodegradable or a combination of biodegradable and non-biodegradable, depending on the desired duration of the reinforcement function of the prosthesis.


If a non permanent reinforcement is desired, the synthetic biocompatible material may be biodegradable. A suitable synthetic biocompatible material may be polylactic acid or copolymers thereof.


If a permanent reinforcement is desired the synthetic biocompatible material may be non biodegradable.


In embodiments, the synthetic biocompatible material is a synthetic non-biodegradable material. Embodiments where the synthetic biocompatible material is non-degradable allow a long term reinforcement of the tissue to be reinforced or repaired.


In embodiments, the biocompatible polymer material is selected from polypropylene, polyethylene terephthalate, and mixtures thereof.


In embodiments, the biocompatible polymer material is polypropylene.


In embodiments, the monofilament has a diameter of from about 0.08 mm to about 0.25 mm, preferably from about 0.10 mm to 0.15 mm, more preferably of about 0.11 mm, 0.12 mm, or 0.13 mm, more preferably 0.12 mm. Such a diameter allows obtaining a good size of the pores and providing the knit with a lightweight and flexible structure, while maintaining good mechanical properties. In embodiments, the monofilament has a diameter of about 0.12 mm.


The knit of the prosthesis of the invention is porous. Knits may comprise openings or pores which may be generated by the pattern followed for the knitting of yarns forming the knit.


In embodiments, the knit of the prosthesis of the invention comprises a plurality of pores having a diameter above 1 mm. In particular, the plurality of pores having a diameter above 1 mm defines an efficient porosity of said knit ranging from about 35% to about 70%, preferably of about 55%.


By “efficient porosity” is meant according to the present application a porosity taking into account only the pores having a diameter above 1 mm, while leaving out the pores having a diameter less or equal to 1 mm. By “pores having a diameter above 1 mm” is meant the pores which have dimensions greater than 1 mm in all directions. The efficient porosity therefore corresponds to the ratio of the area of the totality of the pores having a diameter above 1 mm as defined above to the area of the totality of the knit studied. The pores having a diameter above 1 mm are measured with a profile projector such as a projector 300V from ORAMA. The “efficient porosity” and its measuring method are described in the publication “New objective measurements to characterize the porosity of textile implants”, T. Mühl, M. Binnebösel, U. Klinge and T. Goedderz, Journal of Biomedical Materials Research Part B: Applied Biomaterials, p. 176-183.


The efficient porosity as described above is useful for characterizing the ability of the knit of the prosthesis of the invention to favor cell colonization. Indeed, pores having a diameter above 1 mm are particularly desired for tissue ingrowth after implantation.


In embodiments, the knitting pattern of the knit of the prosthesis of the invention defines a plurality of pores having a diameter ranging above 1 mm. The pores may have a substantially hexagonal or circular shape.


In embodiments, the knit of the invention comprises a plurality of pores having a diameter above 2 mm. Such knits with pores having a diameter above 2 mm favor cell colonization and exhibit a good transparency allowing the surgeon to have a better visibility of the surrounding tissues when he puts the knit/prosthesis in place at the implantation site.


A suitable porous knit for the prosthesis of the invention is for example a knit based on a monofilament of polypropylene of diameter 0.12 mm, the pattern followed for the knitting of said monofilament on a knitting machine having two guide bars B1, B2 being the following, according to the ISO 11676 standard:

    • Bar B1: 1.2/4.5/4.3/4.5/4.3/1.0/1.2/1.0//
    • Bar B2: 4.3/1.0/1.2/1.0/1.2/4.5/4.3/4.5//


Guide bars B1 and B2 may be threaded 1 full 1 empty and may move symmetrically.


The knitting machine may be a warp knitting machine or a raschel knitting machine.


Another suitable knit for the prosthesis of the invention is obtained by knitting a monofilament of polypropylene of diameter 0.10 mm on a warp knitting machine having two guide bars B1, B2, according to the following pattern, according to the ISO 11676 standard:


Bar B1: 5.4/4.3/2.1/0.1/1.2/3.4//


Bar B2: 0.1/1.2/3.4/5.4/4.3/2.1//


Guide bars B1 and B2 are threaded 1 full 1 empty and move symmetrically.


The two above knitting patterns allow obtaining knits suitable for the present invention, having a plurality of pores having a diameter above 1 mm, an efficient porosity ranging from about 35% to about 70%, and a transparency allowing the surgeon to have a good visibility of the implantation site at the time he puts the knit or prosthesis in place.


The knit of the prosthesis of the invention is preferably lightweight. The knit of the prosthesis of the invention preferably shows a mass per unit area ranging from about 30 to about 70 g/m2, preferably ranging from about 36 to about 50 g/m2, and more preferably of about 44 g/m2, 45 g/m2, 46 g/m2, 47 g/m2 or 48 g/m2, measured according to ISO 3801: 1977 «Determination of mass per unit length and mass per unit area», 5 specimens 1 dm2. Such a low mass per unit area allows introducing only a little quantity of foreign material in the body of the patient.


In embodiments, the knit of the prosthesis of the invention has a tensile breaking strength in the warp direction of at least about 200 N, preferably of about 237 N. In embodiments, the knit of the prosthesis of the invention has a tensile breaking strength in the weft direction of at least about 170 N, preferably of about 201 N. In embodiments, the knit of the invention has a bursting strength of at least about 400 kPa, preferably of about 463 kPa. In embodiments, the knit of the prosthesis of the invention has a tear strength in the warp direction of at least about 25 N, preferably of about 30 N. In embodiments, the knit of the prosthesis of the invention has a tear strength in the weft direction of at least about 25 N, preferably of about 37 N. In embodiments, the knit of the prosthesis of the invention has a suture pull out strength in the warp direction of at least about 35 N, preferably of about 46 N. In embodiments, the knit of the prosthesis of the invention has a suture pull out strength in the weft direction of at least about 38 N, preferably of about 42 N. In embodiments, the knit of the prosthesis of the invention has a tensile strength of at least about 42 N/cm, preferably of about 47 N/cm.


The tensile breaking strength (N), the bursting strength (kPa), the tear strength (N), the suture pull out strength (N) and the tensile strength (N/cm) above are measured according to the methods as indicated in the below Examples of the present application.


The porous knit of the prosthesis of the invention shows preferably an homogeneous distribution of shear forces at fixation points. In particular, although it is provided with a lightweight structure, the porous knit of the prosthesis of the invention may show a good resistance to fracture at fixation points compared to lightweight knits of the prior art.


The prosthesis of the invention further comprises a synthetic non porous biodegradable film comprising at least a copolymer of at least ε-caprolactone. The film is intended to cover at least part of the first face of the knit. In embodiments, the synthetic non porous biodegradable film of the prosthesis of the invention entirely covers the first face of the porous knit, and more preferably projects beyond the edges of the knit in such a way as to protect the prosthesis from contacts with adjacent biological tissues, the overshoot being from 5 to 10 millimeters for example. The synthetic non porous biodegradable film of the prosthesis of the invention is intended to minimize post-surgical adhesions on the first face of the knit by occluding the pores present on the surface of said first face. The synthetic non porous biodegradable film of the prosthesis of the invention is preferably continuous and has a smooth and even surface.


In embodiments, the synthetic non porous biodegradable film is a film obtained by extrusion of a composition comprising at least a copolymer of at least ε-caprolactone. In embodiments, the synthetic non porous biodegradable film is a film obtained by extrusion of a composition comprising, preferably consisting in, a random copolymer of glycolide, ε-caprolactone, trimethylene carbonate and lactide.


In embodiments, the synthetic non porous biodegradable film is a film obtained by extrusion of a composition consisting in a random copolymer of from about 68.5 to about 71.5 mole percent glycolide, from about 14.7 to about 17.5 mole percent ε-caprolactone, from about 6.7 to about 8.6 mole percent trimethylene carbonate and from about 4.6 to about 6.5 mole percent lactide. The preparation of copolymer composition suitable for forming the film of the prosthesis of the invention is described in U.S. Pat. No. 6,235,869.


The film may be obtained by flat-die extrusion of the composition comprising at least a copolymer of at least ε-caprolactone in an extruder at a temperature ranging from 170° C. to 210° C. Further to extrusion, the film may be annealed according to conventional methods.


The film of the prosthesis of the invention is biodegradable. In embodiments, the film of the prosthesis of the invention preferably degrades in vivo in less than 15 weeks. A film with such degradation kinetics allows limiting the presence of foreign material within the body of the patient while being efficient with regard to prevention of post-surgical adhesions.


In embodiments, the synthetic non porous biodegradable film shows a thickness ranging from about 15 μm to about 25 μm. In embodiments, the thickness of the film is about 20 μm. In embodiments, the thickness of the film is about 25 μm. Films with such thicknesses constitute efficient adhesion barriers with limited risk of inflammatory response. In addition, films with such thicknesses allow the resulting prosthesis to remain globally thin and soft, and therefore particularly adapted to be folded for easy introduction in a trocar.


The prosthesis of the invention further comprises a synthetic biodegradable binder for bonding the film to the first face of the knit. The binder comprises at least a polymer of ε-caprolactone.


In embodiments, the binder consists in a polymer of ε-caprolactone, in particular in a polymer of ε-caprolactone having a molecular weight of about 80000 g/mol. Such a polymer of ε-caprolactone allows a good binding of the film to the first face of the knit even if the polymer of ε-caprolactone is present in a limited amount. Such a polymer of ε-caprolactone therefore allows obtaining an efficient binding of the film to the first face of the knit while limiting the amount of foreign materials introduced in the body of the patient.


In embodiments, in particular where the binder consists in a polymer of ε-caprolactone, for example in a polymer of ε-caprolactone having a molecular weight of about 80000 g/mol, the binder is present in the prosthesis, in particular between the film and the first face of the knit, in an amount ranging from about 0.60 mg/cm2 to about 0.95 mg/cm2, preferably ranging from about 0.70 mg/cm2 to about 0.85 mg/cm2, more preferably of about 0.83 mg/cm2.


In embodiments, in particular where the binder consists in a polymer of ε-caprolactone, for example in a polymer of ε-caprolactone having a molecular weight of about 80000 g/mol, the binder is present in an amount ranging from 6% to 11% by weight, with respect to the weight of the prosthesis. The binder therefore represents a limited amount of the weight of the prosthesis and a limited amount of additional foreign material introduced in the body of the patient.


The binder is present between said film and said first face under the form of a discontinuous layer. By “discontinuous layer of material” is meant in the present application a plurality of discrete amounts of material which are not linked to each other and which do not form a continuous film. The binder of the prosthesis of the invention is present between said film and said first face under the form of a plurality of discrete amounts of binder which are not linked to each other and which do not form a continuous film. For example, the presence of the binder on the first face of the knit may be limited to the surface of the fibers of the monofilament forming the knit, preferably on the top surface of such fibers, with no binder present in the pores of the knit. In addition, preferably, no binder material is present on the surface of the second face of the knit. The binder therefore may not form a continuous layer between the first face of the knit and the film.


When the binder consists in a polymer of ε-caprolactone, the prosthesis comprises a limited number of different chemical materials, as ε-caprolactone is also a component of the film. This allows limiting the number of different foreign materials introduced in the body of the patient.


A polymer of ε-caprolactone having a molecular weight of about 80000 g/mol suitable for the binder of the prosthesis of the invention is the product commercially available under the code 440744 from company Sigma-Aldrich.


The non porous film of the prosthesis of the invention is intimately linked to the first face of the knit by the binder, although the amount of binder per surface area on the first face of the knit is limited and although the binder may be present under the form of a discontinuous layer.


The prosthesis of the invention may be further provided with one or more marking(s) bearing information that may be useful to the surgeon, in particular at the time of selecting the prosthesis and/or at the time of positioning the prosthesis inside the body of the patient. For example, the marking may indicate the size of the prosthesis, the direction of the longitudinal axis or transversal axis in case the prosthesis is rectangular, the center of the prosthesis, etc. . . . The marking may also indicate to the surgeon the face of the prosthesis which is open to cell colonization or, on the contrary, the face that is covered by the film for minimizing post-surgical adhesions.


In embodiments, the prosthesis is provided with at least a marking made of a synthetic biodegradable material. In embodiments, the marking is located between the binder and the film. In other embodiments, the marking is located between the first face of the knit and the binder. The marking may be present under the form of one piece of marking or several pieces of markings, like letters, digits, spots, dots, geometric figures and the like. In the present application the expression “marked zone” will refer to a zone of the prosthesis, in particular of the first face of the knit, where at least a piece of marking is present.


In embodiments, the total surface area of the marked zones of the prosthesis on a face of the prosthesis may represent from about 0.8% to about 4% of the total surface area of said face of the prosthesis.


In embodiments, the marking is made from a composition consisting in a dye solubilized in a solution of a polymer of ε-caprolactone. In other embodiments, the marking is made from a composition consisting in a dye solubilized in a solution of a copolymer of lactic acid and glycolic acid.


In embodiments, the synthetic biodegradable material forming the marking consists in a polymer of ε-caprolactone and a dye, for example D&C Violet N° 2. In embodiments, the weight ratio of the dye, for example D&C Violet N° 2, to the polymer of ε-caprolactone is equal or less than 1/1000.


In embodiments where the synthetic biodegradable material forming the marking consists in a polymer of ε-caprolactone and a dye, in particular D&C Violet N° 2, the synthetic biodegradable material forming the marking is present, in particular between the first face of the knit and the binder, in an amount ranging from about 3.2 mg/cm2 to about 4.0 mg/cm2, in the marked zones of the prosthesis.


When the synthetic biodegradable material forming the marking consists in a polymer of ε-caprolactone and D&C Violet N° 2, and when the binder consists in a polymer of ε-caprolactone, the amount of polymer of ε-caprolactone and D&C Violet N° 2 in the marked zones of the prosthesis may range from 3.7 mg/cm2 to about 4.6 mg/cm2. In such embodiments, the amount of polymer of ε-caprolactone in the marked zones of the prosthesis remains limited.


When the synthetic biodegradable material forming the marking consists in polymer of ε-caprolactone and a dye, the prosthesis comprises a limited number of different chemical materials, as ε-caprolactone is also a component of the film and of the binder. This allows limiting the number of different foreign materials introduced in the body of the patient.


In addition, when the synthetic biodegradable material forming the marking consists in a polymer of ε-caprolactone and a dye, the degradation kinetics of the synthetic biodegradable material forming the marking is very close to that of the binder. The degradation process of the synthetic biodegradable material forming the marking and of the binder are therefore similar and do not affect each other.


Another aspect of the invention is a method for forming the prosthesis above comprising the following steps:

    • a) providing a porous knit made from a monofilament of a synthetic biocompatible material, said knit defining two opposite faces, a first face and a second face,
    • b) providing a synthetic non porous biodegradable film comprising at least a copolymer of at least ε-caprolactone,
    • c) gluing the first face of the knit with a binding solution comprising at least a polymer of ε-caprolactone, so as to form a discontinuous layer of binding solution on the first face of the knit,
    • d) laminating the film of step b) on the glued first face of the knit.


In a first step of the method of the invention, step a), a porous knit made from a monofilament of a synthetic biocompatible material is provided. Suitable porous knits for the prosthesis of the invention and the method for manufacturing them is described above in the present application.


Following knitting, the knit may be heat-set, for example on a heat-setting machine according to conventional methods.


In a second step of the method of the invention, step b), a synthetic non porous biodegradable film comprising at least a copolymer of at least ε-caprolactone is provided. Suitable films for the prosthesis of the invention and their manufacture method are described above.


In a third step of the method of the invention, step c), the first face of the knit obtained in step a) is glued with a binding solution so as to form a discontinuous layer of binding solution on the first face of the knit.


In embodiments, a composition of a polymer of ε-caprolactone in a solvent such as methylene chloride is used for binding the film to the first face of the knit. For example, the composition is sprayed on the first face of the knit in order to glue said first face of the knit.


In embodiments, the binding solution is a solution of 3% (w/v) of a polymer of ε-caprolactone in methylene chloride. For example, a solution comprising a polymer of ε-caprolactone in an amount of 30 g/L in methylene chloride is used for binding the film to the first face of the knit.


In embodiments, the spraying is performed with a spraying machine «SONOTEK Flexicoat» with a microflow pump. In embodiments, the spraying step may comprise several repeated passes of the spraying nozzle on the first face of the knit.


In embodiments, the binding solution, in particular a solution of 3% (w/v) of a polymer of ε-caprolactone in methylene chloride, is sprayed on the surface of the first face of the knit. In embodiments, the binding solution, in particular a solution of 3% (w/v) of a polymer of ε-caprolactone in methylene chloride, is sprayed on the surface of the first face of the knit so as to form a discontinuous layer of binding solution. In embodiments, the binding solution, in particular a solution of 3% (w/v) of a polymer of ε-caprolactone in methylene chloride, is sprayed on the surface of the first face of the knit at a delivery rate of the solution of about 10 mL/min. The spraying may be repeated several times. For example, the binding solution, in particular a solution of 3% (w/v) of a polymer of ε-caprolactone in methylene chloride, is sprayed on the surface of the first face of the knit via 3 passes of a spraying nozzle, with a delivery rate of the solution of about 10 mL/min for each pass.


In embodiments, during the spraying and subsequent natural drying, the solvent, in particular the methylene chloride, evaporates totally. The binder left on the first face of the knit therefore consists in the polymer of ε-caprolactone.


The spraying conditions of the binding solution, in particular a delivery rate of the solution of about 10 mL/min, allows the binding solution, and in the end the remaining binder after complete evaporation of the solvent such as methylene chloride, to be distributed on the surface of the first face of the knit under the form of a discontinuous layer, and in particular on top of the monofilament fibers of the surface of the first face of the knit, with no binding solution/binder present in the pores present at the surface of said first face of the knit, and with no binding solution/binder present on the surface of the second face of the knit.


In addition, such spraying conditions, for example a delivery rate of the solution of about 10 mL/min and a number of 3 passes, allow obtaining a limited amount of binder in the final product, namely the prosthesis, such as an amount ranging from about 0.60 mg/cm2 to about 0.95 mg/cm2, preferably ranging from about 0.70 mg/cm2 to about 0.85 mg/cm2, more preferably of about 0.83 mg/cm2 between the film and the first face of the knit.


In a fourth step of the method of the invention, step d), the film of step b) is laminated on the glued face of the knit.


The lamination may be performed on a press machine comprising a bottom plate and a top heating plate.


In embodiments, the lamination step is performed by contacting the film of step b) with the glued face of the knit obtained at step c) during a time period ranging from about 30 s to about 7 min, preferably of about 5 minutes, at a temperature of about 105° C. with a contact pressure ranging from about 137895 Pa (20 psi) to about 1034213 Pa (150 psi), preferably of about 172369 Pa (25 psi).


For example, the knit may be positioned on the bottom plate of the machine, with the glued face of the knit in the upward direction. The film obtained at steb b) may then be positioned on the glued face of the knit. The temperature of the top heating plate may be set at about 105° C. The heating plate may be left in contact with the knit and film at the desired contact pressure, for example about 172369 Pa (25 psi), during the desired time period, for example a time period of about 5 minutes.


The method of the invention allows obtaining an efficient bonding of the film to the knit without having to glue the film itself. An additional step of gluing the film is therefore avoided with the method of the invention. The method is therefore simplified with respect to existing methods in which the film needs to be also glued.


In particular, the gluing step conditions and the lamination step conditions of the method of the invention combined with the use of a solution of 3% (w/v) of a polymer of ε-caprolactone in methylene chloride as the binding solution allow obtaining an intimate binding between the film and the first face of the knit, although the amount of binder per surface area between the film and the first face of the knit in the resulting prosthesis may be limited and although the binder in the resulting prosthesis may be present under the form of a discontinuous layer between the film and said first face.


The resulting prosthesis of the invention allows performing an efficient reinforcement of tissue while minimizing post surgical adhesions with reduced number and amount of foreign materials of different compositions that are implanted in the body of the patient.


Before gluing the first face of the knit in view of laminating the film, a printing step may be performed in order to provide the first face of the knit with one or more marking(s).


In embodiments, the printing step comprises positioning a mask on the first face of the knit and spraying a dying solution on the first face of the knit provided with said mask. The mask generally is designed so as to allow one or more part(s) of the first face of the knit to receive the dying composition and therefore be printed while protecting the rest of the surface of said first face. The mask therefore may be designed so as to allow the printing of any desired geometric figures, such as letters, figures, etc. . . . on the first face of the knit.


In embodiments, a composition of a polymer of ε-caprolactone in a solvent such as methylene chloride is used for solubilizing a dye intended to be used as a marking for the prosthesis of the invention. The composition may be sprayed on the first face of the knit provided with a mask. One or more marking(s) are therefore obtained.


In embodiments, a solution comprising a polymer of ε-caprolactone in an amount of 30 g/L in methylene chloride is used for solubilizing 0.03 g/L of dye. In embodiments, the dye is D&C Violet N° 2. In embodiments, a solution comprising a polymer of ε-caprolactone in an amount of 30 g/L in methylene chloride is used for solubilizing 0.03 g/L of D&C Violet N° 2. Such a solution corresponds to a solution of 3% (w/v) of a polymer of ε-caprolactone in methylene chloride and 0.1% (w/w) of D&C Violet N° 2 in a polymer of ε-caprolactone.


In embodiments, the dying solution is a solution of 3% (w/v) of a polymer of ε-caprolactone in methylene chloride and 0.1% (w/w) of D&C Violet N° 2 in a polymer of ε-caprolactone.


In embodiments, the spraying is performed with a spraying machine «SONOTEK Flexicoat» with a microflow pump. In embodiments, the spraying step may comprise repeated passes of the spraying nozzle on the first face of the knit provided with the mask.


In embodiments, the dying solution, in particular a solution of 3% (w/v) of a polymer of ε-caprolactone in methylene chloride and 0.1% (w/w) of D&C Violet N° 2 in a polymer of ε-caprolactone, is sprayed on the surface of the first face of the knit provided with the mask. In embodiments, the dying solution, in particular a solution of 3% (w/v) of a polymer of ε-caprolactone in methylene chloride and 0.1% (w/w) of D&C Violet N° 2 in a polymer of ε-caprolactone, is sprayed on the surface of the first face of the knit provided with the mask with a delivery rate of the solution of about 10 mL/min.


The spraying may be repeated several times depending on the color intensity that is desired for the marking. In embodiments, the dying solution, in particular a solution of 3% (w/v) of a polymer of ε-caprolactone in methylene chloride and 0.1% (w/w) of D&C Violet N° 2 in a polymer of ε-caprolactone, is sprayed via 13 passes of a spraying nozzle on the surface of the first face of the knit provided with the mask, with a delivery rate of the solution of about 10 mL/min.


In embodiments, during the spraying and subsequent natural drying, the solvent, in particular the methylene chloride, evaporates totally. The marking left on the first face of the knit once the mask is removed therefore consists in the polymer of ε-caprolactone and the D&C Violet N° 2.


Such an amount of dying composition and conditions for the printing step allow having simultaneously an efficient marking regarding colorimetric intensity, so that the marking may be easily seen by the surgeons, and a limited amount of foreign materials within the patient body.


In addition, such spraying conditions allow obtaining a limited amount of marking material in the final product, namely the prosthesis, such as an amount ranging from about about 3.2 mg/cm2 to about 4.0 mg/cm2 in the marked zones of the knit.


The prosthesis of the invention may be packaged and sterilized using conventionally known techniques.


The prosthesis of the invention allows performing an efficient reinforcement of tissue while minimizing post surgical adhesions with reduced number and amount of foreign materials of different compositions that are implanted in the body of the patient. The prosthesis of the invention is also particularly efficient regarding cell colonization. The efficient porosity of the porous knit allows an optimal tissue integration on the second face of the knit.


Moreover, the prosthesis of the invention is soft and easily foldable. The prosthesis of the invention may therefore be easily introduced into a trocar and is particularly adapted in laparoscopy surgery.


The prosthesis of the invention can be implanted in intraperitoneal site for ventral hernia repair via open or laparoscopic approach. Fixation to the surrounding tissues can be achieved by stapling, conventional sutures or other means.


Another aspect of the invention is a hernia prosthesis comprising a knit as described above.





BRIEF DESCRIPTION OF DRAWINGS

The present invention will become clearer from the following Examples and drawing in which:



FIG. 1 is a cross section view of an embodiment of a prosthesis of the invention.





DETAILED DESCRIPTION OF EMBODIMENTS
Examples

In all the below examples, the polymer of ε-caprolactone used is a polymer of ε-caprolactone having a molecular weight of about 80000 g/mol commercially available under the product code 440744 from company Sigma-Aldrich.


Example 1

The present example describes the manufacture of knits suitable for the prosthesis of the invention.


1°) Manufacture of Porous Knit A:


Knit A is produced by knitting on a warp knitting machine or a raschel knitting machine having two guide bars B1, B2, a monofilament of polypropylene of diameter 0.12 mm, the pattern followed for the knitting of the monofilament being the following, according to the ISO 11676 standard:


Bar B1: 1.2/4.5/4.3/4.5/4.3/1.0/1.2/1.0//


Bar B2: 4.3/1.0/1.2/1.0/1.2/4.5/4.3/4.5//


Guide bars B1 and B2 are threaded 1 full 1 empty and move symmetrically.


The knitting pattern of Knit A produces pores greater than about 1.0 mm in diameter. For example, some pores of Knit A have an average size of 2.0×2.4 mm. Such a large size of pores is very favorable for cell colonization and confers to Knit A a good transparency allowing a good visibility at the implantation site.)


2°) Manufacture of Porous Knit B:


Knit B is obtained by knitting a monofilament of polypropylene of diameter 0.10 mm on a warp knitting machine having two guide bars B1, B2, according to the following pattern, according to the ISO 11676 standard:


Bar B1: 5.4/4.3/2.1/0.1/1.2/3.4//


Bar B2: 0.1/1.2/3.4/5.4/4.3/2.1//


Guide bars B1 and B2 are threaded 1 full 1 empty and move symmetrically.


After knitting, the knits A and B are heat-set according to conventional methods.)


3°) Properties of Knits A and B:


The following properties of knits A and B have been determined as follows:

    • Mass per unit area (g/m2): measured according to ISO 3801: 1977 «Determination of mass per unit length and mass per unit area», 5 specimens 1 dm2,
    • pore size (width×height) (mm): knit biggest pores are measured making one measurement on 10 individual samples with a profile projector such as a projector 300V from ORAMA,
    • Bursting strength (kPa): measured according to ISO 13938-2: 1999 “Textiles—Bursting properties of textiles—Pneumatic method for determining the bursting strength and bursting deformation”, 5 samples
    • Tensile strength (N/cm) is measured through a plunger test with a traction testing machine such as the Hounsfield model H5KS (Hounsfield, Redhill, England)., crosshead speed: 50 mm/min, 5 samples: the burst pressure can be determined using a circular mesh sample with a radius of Rm=56.4 mm and with a test area of 100 cm2 clamped at the outward boarder (modified DIN 54307 superseded standard). Then, the mesh is loaded with a spherical stamp of a radius Rs=50 mm, velocity v=50 mm/min until rupture occurs. Based on the measured forces and the resulting stretch, the tensile strength (N/cm) can be calculated;
    • Tear strength (N) in the warp direction and in the weft direction: measured according to ISO 4674:1977 “Textiles covered with rubber or plastic—Determination of the tear strength” Method A2, 5 samples, width: 75 mm, Tear length≤145 mm, crosshead speed: 100 mm/min,
    • Thickness: is measured according to ISO 9073-2: 1997 “Textiles—test methods for nonwovens—Part 2: Determination of thickness”, 10 samples, 100×50 mm,
    • Tensile breaking strength and elongation at break: is measured according to ISO 13934-1: 2013 “Textiles—Tensile properties of fabrics—Part 1: Determination of maximum force and elongation at maximum force using the strip method”, 5 samples, width: 50 mm, Length: 200 mm between the jaws, Crosshead speed: 100 mm/min, Pre-load: 0.5 N, using a traction testing machine such as the Hounsfield model HSKS (Hounsfield, Redhill, England);
    • Effective porosity: pores having a diameter above 1 mm are measured with a profile projector such as a projector 300V from ORAMA, 1 sample of 100×50 mm;
    • Suture pull out strength in the warp direction and in the weft direction measured according to NF S94-801: 2007 “Reinforcement implants introduced by the vaginal route for the treatment of stress urinary incontinence and/or of prolapse of the pelvic organs—pre-clinical trials and clinical trials”-§ 5.3.3 5 specimens 50×100 mm, USP 2 suture yarn, crosshead speed: 100 mm/min, using a traction testing machine such as the Hounsfield model H5KS (Hounsfield, Redhill, England).


The results are collected in the following tables:









TABLE I







mechanical properties










Knit A
Knit B












Warp
Warp
Weft
Weft















Tensile breaking
237 ± 6 
187 ± 16
149 ± 10
201 ± 6 


strength (N)


Elongation under
38 ± 1
43 ± 1
59 ± 1
46 ± 0


50N (%)









Bursting strength (kPa)
463 ± 19
361 ± 38











Tear strength (N)
30 ± 1
23 ± 2
22 ± 3
37 ± 5


Suture pull out
46 ± 5
33 ± 1
33 ± 2
42 ± 3


strength (N)









Tensile strength (N/cm)
47 ± 1
40 ± 1
















TABLE II







mass per unit area and porosity










Knit A
Knit B















Mass per unit area (g/cm2)
46
36



Thickness (mm)
0.6
0.4



Pore size (mm) (width ×
2.0 × 2.4
1.6 × 1.4



height)



Efficient porosity (%)
55
35










Example 2

The present example describes the preparation of a marked knit suitable for the prosthesis of the invention.


Knit A of Example 1 is provided with markings in accordance with the following method:


a) Preparation of the Dying Solution:


A mother solution of 0.1% (w/v) of dye in methylene chloride is first prepared as follows: 200 mg of D&C Violet N° 2 are added to 200 mL of methylene chloride with mixing.


The dying solution, under the form of a solution of 3% (w/v) of a polymer of ε-caprolactone in methylene chloride and 0.1% (w/w) of D&C Violet N° 2 in a polymer of ε-caprolactone is then prepared as follows:


18 mL of the mother solution of 0.1% (w/v) of dye in methylene chloride is added to 582 mL of methylene chloride. 18 g of polymer ε-caprolactone are added to the solution with mixing. The mixing is continued until total solubilization of the polymer of ε-caprolactone.


b) Spraying of the Dying Solution:


A mask provided with void zones and filled zones is positioned on a first face of Knit A, namely on the face of Knit A on which it is intended to apply the adhesion barrier film in a subsequent step. The filled zones of the mask are intended to protect the zones of the first face of Knit A that are not intended to be marked. The filled zones of the mask will therefore prevent these zones of the first face of Knit A to be contacted by the dying solution and to be printed. The void zones of the mask are intended to allow the dying solution to reach the zones of the first face of Knit A that are intended to be marked. To the void zones of the mask will correspond the marked zones of the first face of Knit A.


The dying solution prepared in a) above is then sprayed on the first face of Knit A provided with the mask according to the following method: the spraying is performed with an ultrasonic spraying machine «SONOTEK Flexicoat» with a Sonotek 48 KHz Impact Nozzle and a microflow pump with the following conditions:

    • Nozzle speed: 100 mm/s
    • Height of the nozzle with respect to the knit: 40 mm
    • Space between two nozzle passages: 8 mm
    • delivery rate of the solution: 10 mL/min


The spraying is performed under the form of 13 passes of the spraying nozzle. During the spraying, the methylene chloride totally evaporates.


At the end of the 13 passes of the spraying nozzle, and after evaporation of the methylene chloride, the synthetic biodegradable material forming the marking, namely the polymer ε-caprolactone and D&C Violet N° 2, is present on the first face of Knit A in an amount of about 3.50 mg/cm2 in the marked zones of the first face of Knit A.


Such an amount of marking material allows having simultaneously an efficient marking regarding colorimetric intensity, so that the marking may be easily seen by the surgeons, and a limited amount of foreign materials within the patient body.


Example 3

The present example describes the manufacture of a sample of a prosthesis of the invention according to the method of the invention.)


1°) Gluing of Knit A:


The first face of Knit A with marked zones as obtained at EXAMPLE 2 above is glued with a binding solution in accordance with the following method:


A solution of 3% (w/v) of a polymer of ε-caprolactone in methylene chloride is prepared as the binding solution.


The binding solution is then sprayed on the first face of Knit A provided with marked zones according to the following method: the spraying is performed with an ultrasonic spraying machine «SONOTEK Flexicoat» with a Sonotek 48 KHz Impact Nozzle and a microflow pump with the following conditions:

    • Nozzle speed: 100 mm/s
    • Height of the nozzle with respect to the knit: 40 mm
    • Space between two nozzle passages: 8 mm
    • delivery rate of the solution: 10 mL/min


The spraying is performed under the form of 3 passes of the spraying nozzle. During the spraying, the methylene chloride totally evaporates.


Such spraying conditions of the binding solution, in particular a delivery rate of the solution of 10 mL/min, allow the binding solution, and in the end the binder after complete evaporation of the methylene chloride, to be distributed under the form of a discontinuous layer on the surface of the first face of the knit. Indeed, these spraying conditions allow only a limited amount of binding solution to be spread on the first face of Knit A at each pass of the nozzle. The binding solution is therefore not drawn downwards by gravity at each pass and remains significantly on the top surface of the fibers of the face of the knit on which it is sprayed. Thanks to these spraying conditions, the binding solution does not migrate towards the opposite face (second face) of the knit. The binder therefore remains present at the surface of the first face of Knit A and is available for completing an efficient bonding of the film to the first face of the knit once the lamination step is completed (see below).


For example, with spraying conditions where the solution rate is 20 mL/min at each pass of the nozzle, the binding solution is more prone to migrate towards the opposite face of the knit. Less binder is available in the end for performing the bonding between the first face of the knit and the film during the lamination step to come.


At the end of the 3 passes of the spraying nozzle at a delivery rate of the solution of 10 mL/min, and after evaporation of the methylene chloride, the binder, namely the polymer of ε-caprolactone, is present on the first face of Knit A in an amount of about 0.83 mg/cm2 in the non marked zones of the first face of Knit A.


At the end of the 3 passes of the spraying nozzle at a delivery rate of the solution of 10 mL/min, and after evaporation of the methylene chloride, the binder and the marking material, namely the polymer of of ε-caprolactone and D&C Violet N° 2, are present on the first face of Knit A in an amount of about 4.33 mg/cm2 in the marked zones of the first face of Knit A.


As will appear from the description below, such an amount of the binding solution allows obtaining an efficient binding of the film to the knit while limiting the amount of foreign materials in the body of the patient.)


2) Lamination of the Non Porous Film on the Glued Face of Knit A:


A rectangular shaped sample of the marked Knit A above of dimensions 10.5 cm×20.5 cm is prepared.


A non porous biodegradable film comprising at least a copolymer of at least ε-caprolactone under the form of an extruded film obtained by flat-die extrusion of a composition consisting in a random copolymer of from about 68.5 to about 71.5 mole percent glycolide, from about 14.7 to about 17.5 mole percent ε-caprolactone, from about 6.7 to about 8.6 mole percent trimethylene carbonate and from about 4.6 to about 6.5 mole percent lactide, is provided. This film has a thickness of about 20 μm.


A rectangular shaped sample of the film above of dimensions 11 cm×22 cm is prepared.


The lamination is performed with a press from Nelipak comprising a bottom plate and a top heating plate.


The sample of Knit A is positioned on the bottom plate of the machine, with its glued face up.


The sample film is positioned on top of Knit A, so that the surface area on which the pressure is intended to be applied is 20.5 cm×8.5 cm.


A flap of about 3 cm of Knit A and of film is left out of the machine. This flap will not be laminated and will enable performing peel tests on the laminated sample.


The starting pressure of the machine is set up at 1.5 105 Pa (1.5 bar). The temperature of the top heating plate is set at about 105° C. The top heating plate is moved and put in contact with the film so as to press it against the glued face of the knit, and the efficient pressure exerted on the sample is about 172369 Pa (25 psi). The contact time is of 5 minutes.


A synthetic prosthesis of the invention is obtained. The film is intimately linked to the first face of Knit A by the binder, and cannot be delaminated, while at the same time maintaining the porosity open on the second surface of the knit. In particular, the film is intimately linked to the first face of Knit A by the binder, although the amount of binder per surface area on the first face of Knit A is limited.


In the present example, the binder is present in an amount of about 9% by weight, with respect to the weight of the prosthesis.


Wth reference to FIG. 1 is shown a cross section view of the prosthesis 1 of the invention of the present Example obtained by the method of the present Example.


The prosthesis 1 comprises a porous knit 2 (Knit A) made from monofilaments 3 of polypropylene as described above. The knit 2 defines two opposite faces, a first face 4 and a second face 5. The cross section of the knit 2 shown on FIG. 1 shows an alternance of stitches 6, each stitch 6 involving three monofilaments 3, and pores 7.


The prosthesis 1 further comprises a non porous biodegradable film 8, the film as described above, covering the first face 4 of the knit 2. The second face 5 of the knit is left open for cell colonization.


The film 8 is bonded to the first face 4 of the knit 2 by means of the binder 9. As appears on this figure, the binder 9 is under the form of a discontinuous layer of material. In particular, as explained above, the binder 9 is present under the form of a plurality of discrete amounts of binder material which are not linked to each other and which do not form a continuous film. No binder is present in the pores 7 of the knit 2 and no binder is present on the surface of the second face 5 of the knit 2.


The discrete structure of the binder 9 between the first face 4 of the knit 2 and the film 8 allows an improved global tissue integration of the prosthesis 1 after implantation. Indeed, the discontinuous structure of the binder 9 allows the cell colonization to further develop on the first face 4 of the knit 2 when the film 8 begins biodegrade after a few weeks, at a time when post-surgical adhesions are no more likely to occur and the film 8 has completed its function of prevention of adhesions. The cell colonization via the first face of the knit 2, after the non porous film 8 has begun its biodegradation, is therefore not impeded or delayed by the presence of the binder 9.


On FIG. 1 is further shown the marking 10 which is present in a marked zone 11 of the knit 2.)


3°) Peeling Strength:


A peeling test was performed in order to check the peeling strength of the film and to check the efficiency of the bonding between the film and the first face of Knit A. The idea is to measure the energy necessary to peel the film. The higher the necessary energy, the more efficient the bonding between the film and the knit.


The peeling strength measuring method is the following: a traction machine with a bottom fixed jaw and a top mobile jaw is used. The load cell is of 50 N. The distance between the two jaws before the test begins is 3 cm.


A rectangular shaped sample of the knit above is prepared by cutting a strip of 2.54 cm width and 8.5 cm length in the knit above, with maintaining the 3 cm long flap. The free end of the knit of the 3 cm flap described above is grasped within the bottom jaw. The free end of the film of the 3 cm flap described above is grasped within the top jaw. The sample to be tested is placed towards the user of the machine. Before any testing, the jaws are blocked at a pressure of 4 bars to ensure safe grasping of the sample.


The test is performed with the following parameters:

    • Temperature: 20° C.±2° C.,
    • Relative humidity: 65%±4%,
    • Test speed: 250 mm/min,
    • Preload: 0.25 N
    • Preload rate: 50 mm/min


During the testing, the mobile jaw moves away from the fixed jaw. The energy (mJ) necessary for separating the film from the knit with a displacement between 60 mm and 150 mm is measured. The maximum force (N) necessary for delaminating the sample is also measured.


The energy and the maximum force are measured as described above for 15 samples manufactured as described in the present example. The results are the following:


average energy for the 15 samples: 429±37 mJ,


average maximum force for the 15 samples: 6.4±0.6 N


These results confirm that the bonding of the film to the first face of Knit A is efficient. The film of the prosthesis of the invention is therefore very resistant to delamination.


Example 4

Two prostheses, prosthesis P1 and prosthesis P2, were manufactured, both with the Knit A of Example 1 above, the binding solution of Example 3 above and the non porous film of Example 3 above.


For prosthesis P1, the gluing step was completed so as to form a discontinuous layer of the binding solution on the first face of the knit A.


For prosthesis P2, the gluing step was completed by spraying the binding solution both on the first face of the knit A and on the face of the non porous film, so that the binding solution was present between the first face of the knit and the film under the form of a continuous layer of material.


Prostheses P1 and P2 were then submitted to the lamination step.


The structure of the final products were as follows:


in prosthesis P1: the binder was present between the non porous film and the first face of knit A under the form of a discontinuous layer,


in prosthesis P2: the binder was present between the non porous film and the first face of knit A under the form of a continuous layer.


Prostheses P1 and P2 were further surgically implanted in direct contact with subcutaneaous tissue in rats for 4 weeks (9 sites per prosthesis).


Tissue integration of the prostheses was evaluated as follows: a tissue ingrowth score representing a composite score involving consideration of the degree and nature of ongoing inflammation, fibroplasias, fibrosis, angiogenesis, and encapsulation was defined. This parameter and tissue integration has a maximum score of 4 (1=adequate, 2=good, 3=very good, 4=excellent).


Results for P1: overall tissue ingrowth and integration of the implanted prosthesis was very good to excellent (scores ranging from 3 to 4).


Resultas for P2: overall tissue ingrowth and integration of the implanted prosthesis was good to excellent (scores ranging from 2 to 4)


The method of the invention allows obtaining an efficient bonding of film to the first face of the knit while minimizing the presence of foreign materials implanted into the body of the patient.


The resulting prosthesis of the invention allows performing an efficient reinforcement of tissue while minimizing post surgical adhesions with reduced number and amount of foreign materials of different compositions that are implanted in the body of the patient.


The prosthesis of the invention is also particularly efficient regarding cell colonization. The efficient porosity of the knit, in particular of Knit A, allows an optimal tissue integration on the second face of the knit.


Moreover, the prosthesis of the invention is soft and easily foldable. The prosthesis of the invention may therefore be easily introduced into a trocar and is particularly adapted in laparoscopy surgery.

Claims
  • 1. A prosthesis for tissue reinforcement comprising: a lightweight porous knit defining a first face and a second face opposite the first face, the lightweight porous knit having a mass per unit ranging from about 36 to about 50 g/m2 and an efficient porosity ranging from about 35% to about 70%,a synthetic non porous biodegradable film comprising at least a copolymer of at least ε-caprolactone, said film covering at least part of said first face,a synthetic biodegradable binder bonding said film to said first face, said binder comprising at least a polymer of ε-caprolactone, wherein said second face of said lightweight porous knit is left open to cell colonization.
  • 2. A method for forming a prosthesis, comprising the following steps: a) providing a porous knit made from a monofilament of a synthetic biocompatible material, said knit defining two opposite faces, a first face and a second face,b) providing a synthetic non porous biodegradable film comprising at least a copolymer of at least ε-caprolactone,c) gluing the first face of the knit with a binding solution comprising at least a polymer of ε-caprolactone,d) laminating the film of step b) on the glued first face of the knit.
  • 3. The method according to claim 2, wherein the binding solution is a solution of 3% (w/v) of a polymer of ε-caprolactone in methylene chloride.
  • 4. The method according to claim 2, wherein the binding solution is sprayed on a surface of the first face of the knit at a delivery rate of the solution of about 10 mL/min.
  • 5. The method according to claim 2, wherein the binding solution forms a discontinuous layer between the first face of the porous knit and the film.
  • 6. The method according to claim 2, wherein the laminating step d) is performed by contacting the film of step b) with the glued face of the knit obtained at step c) during a time period ranging from about 30 s to about 7 min, at a temperature of about 105° C., with a contact pressure ranging from about 137,895 Pa to about 1,034,213 Pa (150 psi).
  • 7. The method according to claim 6, wherein the contact pressure ranges from about 137,895 Pa to about 172,369 Pa.
  • 8. The method according to claim 2, further comprising a step of printing one or more marking(s) on the first face of the knit, said printing being performed before step c).
  • 9. The method according to claim 8, wherein the step of printing comprises positioning a mask on the first face of the knit and spraying a dying solution on the first face of the knit provided with said mask.
  • 10. The method according to claim 9, wherein the dying solution is a solution of 3% (w/v) of a polymer of ε-caprolactone in methylene chloride and 0.1% of D&C Violet No 2 in a polymer of ε-caprolactone.
  • 11. The method according to claim 10, wherein the dying solution is sprayed on the surface of the first face of the knit provided with the mask with a delivery rate of the solution of about 10 mL/min.
  • 12. The method according to claim 2, wherein providing the porous knit includes knitting the monofilament on a knitting machine.
  • 13. The method according to claim 12, wherein the knitting machine includes two guide-bars B1, B2 following a knit pattern, according to the ISO 11676 standard, including Bar B1: 1.2/4.5/4.3/4.5/4.3/1.0/1.2/1.0//Bar B2: 4.3/1.0/1.2/1.0/1.2/4.5/4.3/4.5//orBar B1: 5.4/4.3/2, 1/0, 1/1.2/3.4//Bar B2: 0.1/1.2/3.4/5.4/4.3/2.1//.
  • 14. The method according to claim 13, wherein the guide-bars B1, B2 are threaded 1 full, 1 empty and move symmetrically.
  • 15. The method according to claim 12, further comprising heat-setting the porous knit following knitting.
Priority Claims (1)
Number Date Country Kind
15305947 Jun 2015 EP regional
CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a divisional of U.S. patent application Ser. No. 15/169,829 filed Jun. 1, 2016, which claims the benefit of and priority to European Patent Application Serial No. 15305947.2 filed Jun. 19, 2015, and the disclosures of each of the above-identified applications are hereby incorporated by reference in their entirety.

US Referenced Citations (461)
Number Name Date Kind
1187158 Mcginley Jun 1916 A
3054406 Usher Sep 1962 A
3118294 Van Laethem Jan 1964 A
3124136 Usher Mar 1964 A
3272204 Artandi et al. Sep 1966 A
3276448 Kronenthal Oct 1966 A
3320649 Naimer May 1967 A
3364200 Ashton et al. Jan 1968 A
3570482 Shigeru et al. Mar 1971 A
3718725 Hamano Feb 1973 A
4006747 Kronenthal et al. Feb 1977 A
4060081 Yannas et al. Nov 1977 A
4173131 Melton et al. Nov 1979 A
4193137 Heck Mar 1980 A
4248064 Odham Feb 1981 A
4294241 Miyata Oct 1981 A
4307717 Hymes et al. Dec 1981 A
4338800 Matsuda Jul 1982 A
4476697 Schafer et al. Oct 1984 A
4487865 Balazs et al. Dec 1984 A
4500676 Balazs et al. Feb 1985 A
4511653 Play et al. Apr 1985 A
4527404 Nakagaki et al. Jul 1985 A
4591501 Cioca May 1986 A
4597762 Walter et al. Jul 1986 A
4603695 Ikada et al. Aug 1986 A
4631932 Sommers Dec 1986 A
4670014 Huc et al. Jun 1987 A
4709562 Matsuda Dec 1987 A
4748078 Doi et al. May 1988 A
4759354 Quarfoot Jul 1988 A
4769038 Bendavid et al. Sep 1988 A
4796603 Dahlke et al. Jan 1989 A
4813942 Alvarez Mar 1989 A
4841962 Berg et al. Jun 1989 A
4854316 Davis Aug 1989 A
4925294 Geshwind et al. May 1990 A
4931546 Tardy et al. Jun 1990 A
4942875 Hlavacek et al. Jul 1990 A
4948540 Nigam Aug 1990 A
4950483 Ksander et al. Aug 1990 A
4970298 Silver et al. Nov 1990 A
4976737 Leake Dec 1990 A
5002551 Linsky et al. Mar 1991 A
5015584 Brysk May 1991 A
5116357 Eberbach May 1992 A
5147374 Fernandez Sep 1992 A
5162430 Rhee et al. Nov 1992 A
5171273 Silver et al. Dec 1992 A
5176692 Wilk et al. Jan 1993 A
5192301 Kamiya et al. Mar 1993 A
5195542 Gazielly et al. Mar 1993 A
5196185 Silver et al. Mar 1993 A
5201745 Tayot et al. Apr 1993 A
5201764 Kelman et al. Apr 1993 A
5206028 Li Apr 1993 A
5217493 Raad et al. Jun 1993 A
5254133 Seid Oct 1993 A
5256418 Kemp et al. Oct 1993 A
5258000 Gianturco Nov 1993 A
5263983 Yoshizato et al. Nov 1993 A
5304595 Rhee et al. Apr 1994 A
5306500 Rhee et al. Apr 1994 A
5324775 Rhee et al. Jun 1994 A
5328955 Rhee et al. Jul 1994 A
5334527 Brysk Aug 1994 A
5339657 Mcmurray Aug 1994 A
5350583 Yoshizato et al. Sep 1994 A
5356432 Rutkow et al. Oct 1994 A
5368549 Mcvicker Nov 1994 A
5368602 Torre Nov 1994 A
5370650 Jonathan et al. Dec 1994 A
5376375 Rhee et al. Dec 1994 A
5376376 Li Dec 1994 A
5397331 Himpens et al. Mar 1995 A
5399361 Song et al. Mar 1995 A
5413791 Rhee et al. May 1995 A
5425740 Hutchinson, Jr. Jun 1995 A
5428022 Palefsky et al. Jun 1995 A
5433996 Kranzler et al. Jul 1995 A
5441491 Verschoor et al. Aug 1995 A
5441508 Gazielly et al. Aug 1995 A
5456693 Conston et al. Oct 1995 A
5456711 Hudson Oct 1995 A
5466462 Rosenthal et al. Nov 1995 A
5480644 Freed Jan 1996 A
5487895 Dapper et al. Jan 1996 A
5490984 Freed Feb 1996 A
5512291 Li Apr 1996 A
5512301 Song et al. Apr 1996 A
5514181 Light et al. May 1996 A
5522840 Krajicek Jun 1996 A
5523348 Rhee et al. Jun 1996 A
5536656 Kemp et al. Jul 1996 A
5543441 Rhee et al. Aug 1996 A
5565210 Rosenthal et al. Oct 1996 A
5567806 Abdul-Malak et al. Oct 1996 A
5569273 Titone et al. Oct 1996 A
RE35399 Eisenberg Dec 1996 E
5593441 Lichtenstein et al. Jan 1997 A
5595621 Light et al. Jan 1997 A
5601571 Moss Feb 1997 A
5607474 Athanasiou et al. Mar 1997 A
5607590 Shimizu Mar 1997 A
5614587 Rhee et al. Mar 1997 A
5618551 Tardy et al. Apr 1997 A
5634931 Kugel Jun 1997 A
5639796 Lee Jun 1997 A
5665391 Lea Sep 1997 A
5667839 Berg Sep 1997 A
5676967 Williams et al. Oct 1997 A
5681568 Goldin et al. Oct 1997 A
5686090 Schilder et al. Nov 1997 A
5686115 Vournakis et al. Nov 1997 A
5690675 Sawyer et al. Nov 1997 A
5695525 Mulhauser et al. Dec 1997 A
5697978 Sgro Dec 1997 A
5700476 Rosenthal et al. Dec 1997 A
5700477 Rosenthal et al. Dec 1997 A
5702416 Kieturakis et al. Dec 1997 A
5709934 Bell et al. Jan 1998 A
5711960 Shikinami Jan 1998 A
5716409 Debbas Feb 1998 A
5720981 Eisinger Feb 1998 A
5732572 Litton Mar 1998 A
5743917 Saxon Apr 1998 A
5749895 Sawyer et al. May 1998 A
5752974 Rhee et al. May 1998 A
5766246 Mulhauser et al. Jun 1998 A
5766631 Arnold Jun 1998 A
5769864 Kugel Jun 1998 A
5771716 Schlussel Jun 1998 A
5785983 Furlan et al. Jul 1998 A
5800541 Rhee et al. Sep 1998 A
5814328 Gunasekaran Sep 1998 A
5833705 Ken et al. Nov 1998 A
5840011 Landgrebe et al. Nov 1998 A
5861034 Taira et al. Jan 1999 A
5863984 Doillon et al. Jan 1999 A
5869080 Mcgregor et al. Feb 1999 A
5871767 Dionne et al. Feb 1999 A
5876444 Lai Mar 1999 A
5891558 Bell et al. Apr 1999 A
5899909 Claren et al. May 1999 A
5906937 Sugiyama et al. May 1999 A
5910149 Kuzmak Jun 1999 A
5911731 Pham et al. Jun 1999 A
5916225 Kugel Jun 1999 A
5919232 Chaffringeon et al. Jul 1999 A
5919233 Knopf et al. Jul 1999 A
5922026 Chin Jul 1999 A
5931165 Reich et al. Aug 1999 A
5942278 Hagedorn et al. Aug 1999 A
5962136 Dewez et al. Oct 1999 A
5972022 Huxel Oct 1999 A
RE36370 Li Nov 1999 E
5993844 Abraham et al. Nov 1999 A
5994325 Roufa et al. Nov 1999 A
5997895 Narotam et al. Dec 1999 A
6001895 Harvey et al. Dec 1999 A
6008292 Lee et al. Dec 1999 A
6015844 Harvey et al. Jan 2000 A
6039686 Robert Mar 2000 A
6042534 Gellman et al. Mar 2000 A
6042592 Schmitt Mar 2000 A
6043089 Sugiyama et al. Mar 2000 A
6051425 Morota et al. Apr 2000 A
6056688 Benderev et al. May 2000 A
6056970 Greenawalt et al. May 2000 A
6057148 Sugiyama et al. May 2000 A
6063396 Kelleher May 2000 A
6066776 Goodwin et al. May 2000 A
6066777 Benchetrit May 2000 A
6071292 Makower et al. Jun 2000 A
6077281 Das Jun 2000 A
6080194 Pachence et al. Jun 2000 A
6083522 Chu et al. Jul 2000 A
6090116 D Aversa et al. Jul 2000 A
6113623 Sgro Sep 2000 A
6120539 Eldridge et al. Sep 2000 A
6132765 Dicosmo et al. Oct 2000 A
6143037 Goldstein et al. Nov 2000 A
6153292 Bell et al. Nov 2000 A
6162962 Hinsch et al. Dec 2000 A
6165488 Tardy et al. Dec 2000 A
6171318 Kugel et al. Jan 2001 B1
6174320 Kugel et al. Jan 2001 B1
6176863 Kugel et al. Jan 2001 B1
6179872 Bell et al. Jan 2001 B1
6180848 Flament et al. Jan 2001 B1
6197325 Macphee et al. Mar 2001 B1
6197934 Devore et al. Mar 2001 B1
6197935 Doillon et al. Mar 2001 B1
6210439 Firmin et al. Apr 2001 B1
6214020 Mulhauser et al. Apr 2001 B1
6221109 Geistlich et al. Apr 2001 B1
6224616 Kugel May 2001 B1
6241768 Agarwal et al. Jun 2001 B1
6258124 Darois et al. Jul 2001 B1
6262332 Ketharanathan Jul 2001 B1
6264702 Ory et al. Jul 2001 B1
6267772 Mulhauser et al. Jul 2001 B1
6270530 Eldridge et al. Aug 2001 B1
6277397 Shimizu Aug 2001 B1
6280453 Kugel et al. Aug 2001 B1
6287316 Agarwal et al. Sep 2001 B1
6290708 Kugel et al. Sep 2001 B1
6306079 Trabucco Oct 2001 B1
6306424 Vyakarnam et al. Oct 2001 B1
6312474 Francis et al. Nov 2001 B1
6319264 Tormala et al. Nov 2001 B1
6328686 Robert Dec 2001 B1
6334872 Termin et al. Jan 2002 B1
6383201 Dong May 2002 B1
6391060 Ory et al. May 2002 B1
6391333 Li et al. May 2002 B1
6391939 Tayot et al. May 2002 B2
6408656 Ory et al. Jun 2002 B1
6410044 Chudzik et al. Jun 2002 B1
6413742 Olsen et al. Jul 2002 B1
6425924 Rousseau Jul 2002 B1
6428978 Olsen et al. Aug 2002 B1
6436030 Rehil Aug 2002 B2
6440167 Shimizu Aug 2002 B2
6443964 Ory et al. Sep 2002 B1
6447551 Goldmann Sep 2002 B1
6447802 Sessions et al. Sep 2002 B2
6448378 Devore et al. Sep 2002 B2
6451032 Ory et al. Sep 2002 B1
6451301 Sessions et al. Sep 2002 B1
6454787 Maddalo et al. Sep 2002 B1
6477865 Matsumoto Nov 2002 B1
6479072 Morgan et al. Nov 2002 B1
6485503 Jacobs et al. Nov 2002 B2
6500464 Ceres et al. Dec 2002 B2
6500777 Wiseman et al. Dec 2002 B1
6509031 Miller et al. Jan 2003 B1
6511958 Atkinson et al. Jan 2003 B1
6514286 Leatherbury et al. Feb 2003 B1
6514514 Atkinson et al. Feb 2003 B1
6540773 Dong Apr 2003 B2
6541023 Andre et al. Apr 2003 B1
6548077 Gunasekaran Apr 2003 B1
6554855 Dong Apr 2003 B1
6559119 Burgess et al. May 2003 B1
6566345 Miller et al. May 2003 B2
6575988 Rousseau Jun 2003 B2
6576019 Atala Jun 2003 B1
6596002 Therin et al. Jul 2003 B2
6596304 Bayon et al. Jul 2003 B1
6599323 Melican et al. Jul 2003 B2
6599524 Li et al. Jul 2003 B2
6599690 Abraham et al. Jul 2003 B1
6610006 Amid et al. Aug 2003 B1
6613348 Jain Sep 2003 B1
6616685 Rousseau Sep 2003 B2
6623963 Mueller et al. Sep 2003 B1
6630414 Matsumoto Oct 2003 B1
6637437 Hungerford et al. Oct 2003 B1
6638284 Rousseau et al. Oct 2003 B1
6645226 Jacobs et al. Nov 2003 B1
6652594 Francis et al. Nov 2003 B2
6652595 Nicolo Nov 2003 B1
6653450 Berg et al. Nov 2003 B1
6656206 Corcoran et al. Dec 2003 B2
6660280 Allard et al. Dec 2003 B1
6669735 Pelissier Dec 2003 B1
6670018 Fujita et al. Dec 2003 B2
6682760 Noff et al. Jan 2004 B2
6685714 Rousseau Feb 2004 B2
6706684 Bayon et al. Mar 2004 B1
6706690 Reich et al. Mar 2004 B2
6712859 Rousseau et al. Mar 2004 B2
6719795 Bryan et al. Apr 2004 B1
6723335 Moehlenbruck et al. Apr 2004 B1
6726660 Hessel et al. Apr 2004 B2
6730299 Tayot et al. May 2004 B1
6736823 Darois et al. May 2004 B2
6736854 Vadurro et al. May 2004 B2
6737371 Planck et al. May 2004 B1
6743435 Devore et al. Jun 2004 B2
6746458 Cloud Jun 2004 B1
6752834 Geistlich et al. Jun 2004 B2
6755868 Rousseau Jun 2004 B2
6773723 Spiro et al. Aug 2004 B1
6783554 Amara et al. Aug 2004 B2
6790213 Cherok et al. Sep 2004 B2
6790454 Abdul et al. Sep 2004 B1
6800082 Rousseau Oct 2004 B2
6833408 Sehl et al. Dec 2004 B2
6835336 Watt Dec 2004 B2
6852330 Bowman et al. Feb 2005 B2
6869938 Schwartz et al. Mar 2005 B1
6872227 Sump et al. Mar 2005 B2
6893653 Abraham et al. May 2005 B2
6896904 Spiro et al. May 2005 B2
6926723 Mulhauser et al. Aug 2005 B1
6936276 Spiro et al. Aug 2005 B2
6939562 Spiro et al. Sep 2005 B2
6949625 Tayot Sep 2005 B2
6966918 Schuldt-Hempe et al. Nov 2005 B1
6971252 Therin et al. Dec 2005 B2
6974679 Andre et al. Dec 2005 B2
6974862 Ringeisen et al. Dec 2005 B2
6977231 Matsuda Dec 2005 B1
6984392 Bechert et al. Jan 2006 B2
6988386 Okawa et al. Jan 2006 B1
7011688 Gryska et al. Mar 2006 B2
7021086 Ory et al. Apr 2006 B2
7022358 Eckmayer et al. Apr 2006 B2
7025063 Snitkin et al. Apr 2006 B2
7041868 Greene et al. May 2006 B2
7060103 Carr et al. Jun 2006 B2
RE39172 Bayon et al. Jul 2006 E
7070558 Gellman et al. Jul 2006 B2
7087065 Ulmsten et al. Aug 2006 B2
7094261 Zotti et al. Aug 2006 B2
7098315 Schaufler Aug 2006 B2
7101381 Ford et al. Sep 2006 B2
7115220 Dubson et al. Oct 2006 B2
7156804 Nicolo Jan 2007 B2
7156858 Schuldt-Hempe et al. Jan 2007 B2
7175852 Simmoteit et al. Feb 2007 B2
7192604 Brown et al. Mar 2007 B2
7207962 Anand et al. Apr 2007 B2
7214765 Ringeisen et al. May 2007 B2
7226611 Yura et al. Jun 2007 B2
7229453 Anderson et al. Jun 2007 B2
7252837 Guo et al. Aug 2007 B2
7279177 Looney et al. Oct 2007 B2
7331199 Ory et al. Feb 2008 B2
7393319 Merade et al. Jul 2008 B2
7556598 Rao Jul 2009 B2
7594921 Browning Sep 2009 B2
7614258 Cherok et al. Nov 2009 B2
7615065 Priewe et al. Nov 2009 B2
7662169 Wittmann Feb 2010 B2
7670380 Cauthen, III et al. Mar 2010 B2
7682381 Rakos et al. Mar 2010 B2
7709017 Tayot et al. May 2010 B2
7718556 Matsuda et al. May 2010 B2
7732354 Fricke et al. Jun 2010 B2
7785334 Ford et al. Aug 2010 B2
7789888 Bartee et al. Sep 2010 B2
7799767 Lamberti et al. Sep 2010 B2
7806905 Ford et al. Oct 2010 B2
7824420 Eldridge et al. Nov 2010 B2
7828854 Rousseau et al. Nov 2010 B2
7900484 Cherok et al. Mar 2011 B2
7931695 Ringeisen Apr 2011 B2
8052759 Dupic et al. Nov 2011 B2
8079023 Chen Dec 2011 B2
8100924 Browning Jan 2012 B2
8123817 Intoccia et al. Feb 2012 B2
8142515 Therin et al. Mar 2012 B2
8157821 Browning Apr 2012 B2
8157822 Browning Apr 2012 B2
8182545 Cherok et al. May 2012 B2
8197837 Jamiolkowski et al. Jun 2012 B2
8206632 Rousseau et al. Jun 2012 B2
8215310 Browning Jul 2012 B2
8317872 Adams Nov 2012 B2
8323675 Greenawalt Dec 2012 B2
8343232 Adzich et al. Jan 2013 B2
8366787 Brown et al. Feb 2013 B2
8435307 Paul May 2013 B2
8470355 Skalla et al. Jun 2013 B2
8562633 Cully et al. Oct 2013 B2
8574627 Martakos et al. Nov 2013 B2
8709094 Stad et al. Apr 2014 B2
8734471 Deitch May 2014 B2
8753360 Gleiman et al. Jun 2014 B2
8758800 Stopek et al. Jun 2014 B2
8784294 Goddard Jul 2014 B2
8814887 Walther et al. Aug 2014 B2
8828092 Toso et al. Sep 2014 B2
8834864 Odar et al. Sep 2014 B2
8846060 Archibald et al. Sep 2014 B2
8865215 Ladet et al. Oct 2014 B2
8877233 Obermiller et al. Nov 2014 B2
8911504 Mathisen et al. Dec 2014 B2
8920370 Sholev et al. Dec 2014 B2
8956373 Ford et al. Feb 2015 B2
8962006 Bayon et al. Feb 2015 B2
8968762 Ladet et al. Mar 2015 B2
8979935 Lozier et al. Mar 2015 B2
9034357 Stopek May 2015 B2
9113993 Lee Aug 2015 B2
9211175 Stopek et al. Dec 2015 B2
9216075 Bailly et al. Dec 2015 B2
20020087174 Capello Jul 2002 A1
20020095218 Carr et al. Jul 2002 A1
20030086975 Ringeisen May 2003 A1
20030106346 Matsumoto Jun 2003 A1
20030114937 Leatherbury et al. Jun 2003 A1
20030133967 Ruszczak et al. Jul 2003 A1
20030225355 Butler Dec 2003 A1
20040034373 Schuldt-Hempe et al. Feb 2004 A1
20040054376 Ory et al. Mar 2004 A1
20040059356 Gingras Mar 2004 A1
20040101546 Gorman et al. May 2004 A1
20050002893 Goldmann Jan 2005 A1
20050021058 Negro Jan 2005 A1
20050085924 Darois et al. Apr 2005 A1
20050113849 Popadiuk et al. May 2005 A1
20050137512 Campbell et al. Jun 2005 A1
20050142161 Freeman et al. Jun 2005 A1
20050148963 Brennan Jul 2005 A1
20050175659 Macomber et al. Aug 2005 A1
20050232979 Shoshan Oct 2005 A1
20050267521 Forsberg Dec 2005 A1
20050288691 Leiboff Dec 2005 A1
20060116696 Odermatt et al. Jun 2006 A1
20060135921 Wiercinski et al. Jun 2006 A1
20060147501 Hillas et al. Jul 2006 A1
20060216320 Kitazono et al. Sep 2006 A1
20060252981 Matsuda et al. Nov 2006 A1
20060253203 Alvarado Nov 2006 A1
20060282103 Fricke et al. Dec 2006 A1
20070088391 Mcalexander et al. Apr 2007 A1
20070129736 Solecki Jun 2007 A1
20070198040 Buevich et al. Aug 2007 A1
20070299538 Roeber Dec 2007 A1
20080091276 Deusch et al. Apr 2008 A1
20080109017 Herweck et al. May 2008 A1
20080113001 Herweck et al. May 2008 A1
20080172071 Barker Jul 2008 A1
20080255593 St-Germain Oct 2008 A1
20090035341 Wagener et al. Feb 2009 A1
20090036996 Roeber Feb 2009 A1
20090068250 Gravagna et al. Mar 2009 A1
20090105526 Piroli et al. Apr 2009 A1
20090163936 Yang et al. Jun 2009 A1
20090187197 Roeber et al. Jul 2009 A1
20090192530 Adzich et al. Jul 2009 A1
20090204129 Fronio Aug 2009 A1
20090216338 Gingras et al. Aug 2009 A1
20090270999 Brown Oct 2009 A1
20090281558 Li et al. Nov 2009 A1
20090318752 Evans et al. Dec 2009 A1
20100104608 Abuzaina et al. Apr 2010 A1
20100318108 Datta Dec 2010 A1
20110015760 Kullas Jan 2011 A1
20110144667 Horton et al. Jun 2011 A1
20110190795 Hotter et al. Aug 2011 A1
20110238094 Thomas et al. Sep 2011 A1
20110251699 Ladet et al. Oct 2011 A1
20110257666 Ladet et al. Oct 2011 A1
20120016388 Houard et al. Jan 2012 A1
20120029537 Mortarino Feb 2012 A1
20120065727 Reneker et al. Mar 2012 A1
20120082712 Stopek et al. Apr 2012 A1
20120116425 Intoccia et al. May 2012 A1
20120150204 Mortarino et al. Jun 2012 A1
20120165937 Montanari et al. Jun 2012 A1
20120179175 Hammell et al. Jul 2012 A1
20120179176 Wilson et al. Jul 2012 A1
20120197415 Montanari et al. Aug 2012 A1
20140005341 Tang Jan 2014 A1
20140044861 Boey et al. Feb 2014 A1
20140364684 Lecuivre et al. Dec 2014 A1
Foreign Referenced Citations (140)
Number Date Country
1317836 May 1993 CA
201879864 Jun 2011 CN
19544162 Apr 1997 DE
19718903 Dec 1997 DE
19751733 Dec 1998 DE
19832634 Jan 2000 DE
10019604 Oct 2001 DE
10120942 Oct 2001 DE
10043396 Jun 2002 DE
0194192 Sep 1986 EP
0248544 Dec 1987 EP
0263360 Apr 1988 EP
0276890 Aug 1988 EP
0372969 Jun 1990 EP
0531742 Mar 1993 EP
0544485 Jun 1993 EP
0552576 Jul 1993 EP
0611561 Aug 1994 EP
0614650 Sep 1994 EP
0621014 Oct 1994 EP
0625891 Nov 1994 EP
0637452 Feb 1995 EP
0664132 Jul 1995 EP
0705878 Apr 1996 EP
0719527 Jul 1996 EP
0774240 May 1997 EP
0797962 Oct 1997 EP
0800791 Oct 1997 EP
0827724 Mar 1998 EP
0836838 Apr 1998 EP
0847727 Jun 1998 EP
0876808 Nov 1998 EP
0895762 Feb 1999 EP
0898944 Mar 1999 EP
1017415 Jul 2000 EP
1036545 Sep 2000 EP
1052319 Nov 2000 EP
1055757 Nov 2000 EP
1090590 Apr 2001 EP
1216717 Jun 2002 EP
1216718 Jun 2002 EP
0693523 Nov 2002 EP
1273312 Jan 2003 EP
1315468 Jun 2003 EP
1382728 Jan 2004 EP
1484070 Dec 2004 EP
1561480 Aug 2005 EP
1645232 Apr 2006 EP
1674048 Jun 2006 EP
1691606 Aug 2006 EP
1782848 May 2007 EP
2229918 Sep 2010 EP
2792351 Oct 2014 EP
2244853 Apr 1975 FR
2257262 Aug 1975 FR
2308349 Nov 1976 FR
2453231 Oct 1980 FR
2612392 Sep 1988 FR
2715309 Jul 1995 FR
2715405 Jul 1995 FR
2724563 Mar 1996 FR
2730406 Aug 1996 FR
2744906 Aug 1997 FR
2766698 Feb 1999 FR
2771622 Jun 1999 FR
2773057 Jul 1999 FR
2774277 Aug 1999 FR
2779937 Dec 1999 FR
2859624 Dec 2005 FR
2876020 Apr 2006 FR
2863277 Jun 2006 FR
2884706 Apr 2008 FR
2929834 Oct 2009 FR
2953709 Jun 2011 FR
1174814 Dec 1969 GB
2051153 Jan 1981 GB
2306110 Apr 1997 GB
H0332677 Mar 1991 JP
H05237128 Sep 1993 JP
H09137380 May 1997 JP
H11146888 Jun 1999 JP
2008538300 Oct 2008 JP
2011078767 Apr 2011 JP
2013535244 Sep 2013 JP
2014514037 Jun 2014 JP
8902445 Mar 1989 WO
8908467 Sep 1989 WO
9012551 Nov 1990 WO
9206639 Apr 1992 WO
9220349 Nov 1992 WO
9310731 Jun 1993 WO
9311805 Jun 1993 WO
9318174 Sep 1993 WO
9417747 Aug 1994 WO
9507666 Mar 1995 WO
9518638 Jul 1995 WO
9532687 Dec 1995 WO
9603091 Feb 1996 WO
9608277 Mar 1996 WO
9609795 Apr 1996 WO
9614805 May 1996 WO
9641588 Dec 1996 WO
9735533 Oct 1997 WO
9835632 Aug 1998 WO
9849967 Nov 1998 WO
9905990 Feb 1999 WO
9906079 Feb 1999 WO
9906080 Feb 1999 WO
9951163 Oct 1999 WO
0016821 Mar 2000 WO
0067663 Nov 2000 WO
0115625 Mar 2001 WO
0180773 Nov 2001 WO
0181667 Nov 2001 WO
0207648 Jan 2002 WO
0217853 Mar 2002 WO
02078568 Oct 2002 WO
03002168 Jan 2003 WO
2004004600 Jan 2004 WO
2004071349 Aug 2004 WO
2004078120 Sep 2004 WO
2004103212 Dec 2004 WO
2005011280 Feb 2005 WO
2005013863 Feb 2005 WO
2005018698 Mar 2005 WO
2005048708 Jun 2005 WO
2005105172 Nov 2005 WO
2006018552 Feb 2006 WO
2006023444 Mar 2006 WO
2006032812 Mar 2006 WO
2009071998 Jun 2009 WO
2009031035 Jan 2010 WO
2010043978 Apr 2010 WO
2010088699 Aug 2010 WO
2007048099 Sep 2010 WO
2011007062 Jan 2011 WO
2011026987 Mar 2011 WO
2011038740 Apr 2011 WO
2012007578 Jan 2012 WO
2012123582 Sep 2012 WO
Non-Patent Literature Citations (35)
Entry
Notification of the First Office Action issued in Chinese Patent Application No. 201610439577.1 dated May 20, 2020, 19 pages; with Eng. translation.
Amid, P., “Lichtenstein tension-free hernioplasty Its inception, evolution, and principles,” Hernia, 2004; pp. 1-7, 8, published online Sep. 2003.
Blondin, C. et al., “Inhibition of Complement Activation by Natural Sulfated Polysaccharides (Fucans) from Brown Seaweed,” Molecular Immuol., Mar. 1994, pp. 247-253, 31(4).
Blondin, C. et al., “Relationships between chemical characteristics and anticomplementary activity of fucans,” Biomaterials, Mar. 1996, pp. 597-603, 17(6).
Boisson-Vidal, C. et al., “Neoangiogenesis Induced by Progenitor Endothelial Cells: Effect of Fucoidan From Marine Algae,” Cardiovascular & Hematological Agents in Medicinal Chem., Jan. 2007, pp. 67-77, 5(1).
Bracco, P. et al., “Comparison of polypropylene and polyethylene terephthalate (Dacron) meshes for abdominal wall hernia repair: A chemical and morphological study,” Hernia, 2005, pp. 51-55, 9 (1), published online Sep. 2004.
Chen, G. et al., “A Hybrid Network of Synthetic Polymer Mesh and Collagen Sponge,” The Royal Society of Chemistry 2000, Chem. Commun., Jul. 2000, pp. 1505-1506.
Collins, R. et al., “Use of collagen film as a dural substitute: Preliminary animal studies,” Journal of Biomedical Materials Research, Feb. 1991, pp. 267-276, vol. 25.
Dr. S. Raz, “The Karl Mayer Guide to Tehnical Textiles,” Jan. 2000, pp. 1-36, Obertshausen, Germany.
European Search Report for EP 15 30 5947 date of completion is Nov. 25, 2015 (4 pages).
Examination report No. 1 for standard patent application issued in Australian Patent Application No. 2016203147 dated Feb. 13, 2020, 4 pages.
Haneji, K. et al., “Fucoidan extracted from Cladosiphon Okamuranus Tokida Induces Apoptosis of Human T-cell Leukemia Virus Type 1-Infected T-Cell Lines and Primary Adult T-Cell Leukemia Cells,” Nutrition and Cancer, 2005, pp. 189-201, 52(2), published online Nov. 2009.
Haroun-Bouhedja, F. et al., “In Vitro Effects of Fucans on MDA-MB231 Tumor Cell Adhesion and Invasion,” Anticancer Res., Jul.-Aug. 2002, pp. 2285-2292, 22(4).
Haroun-Bouhedja, F. et al., “Relationship between sulfate groups and biological activities of fucans,” Thrombosis Res., Dec. 2000, pp. 453-459, 100(5).
Hirano, S. et al., “The blood biocompatibility of chitosan and N-acylchitosans,” J. Biomed. Mater. Res., Apr. 1985, 413-417, 19.
Junge, K. et al., “Functional and Morphologic Properties of a Modified Mesh for Inguinal Hernia Repair,” World J. Surg., Sep. 2002, pp. 1472-1480, 26.
Kanabar, V. et al., “Some structural determinants of the antiproliferative effect of heparin-like molecules on human airway smooth muscle,” Br. J. Pharmacol., Oct. 2005, pp. 370-777, 146(3).
Klinge, U. et al., “Foreign Body Reaction to Meshes Used for the Repair of Abdominal Wall Hernias,” Eur J. Surg, Sep. 1999, pp. 665-673, 165.
Klinge, U. et al., “Functional and Morphological Evaluation of a Low-Weight, Monofilament Polypropylene Mesh for Hernia Repair,” J. Biomed. Mater. Res., Jan. 2002, pp. 129-136, 63.
Langenbech, M. R. et al., “Comparison of biomaterials in the early postoperative period,” Surg Endosc., May 2003, pp. 1105-1109, 17 (7).
Logeart, D. et al., “Fucans, sulfated polysaccharides extracted from brown seaweeds, inhibit vascular smooth muscle cell proliferation. II. Degradation and molecular weight effect,” Eur. J. Cell. Biol., Dec. 1997, pp. 385-390, 74(4).
Malette, W. G. et al., “Chitosan, a New Hemostatic,” Ann Th. Surg., Jul. 1983, pp. 55-58, 36.
Mühl, T. et al., “New Objective Measurement to Characterize the Porosity of Textile Implants,” Journal of Biomedical Materials Research Part B: Applied Biomaterials, May 2007, pp. 176-183.
Muzzarelli, R. et al., “Reconstruction of parodontal tissue with chitosan,” Biomaterials, Nov. 1989, pp. 598-604, 10.
Notice of Reasons for Rejection issued in Japanese Patent Application No. 2016-108408 dated Feb. 17, 2020, with English translations, 8 pages.
O'Dwyer, P. et al., “Randomized clinical trial assessing impact of a lightweight or heavyweight mesh on chronic pain after inguinal hernia repair,” Br. J. Surg., Feb. 2005, pp. 166-170, 92(2).
Prokop, A. et al., “Water Soluble Polymers for Immunoisolation I: Complex Coacevation and Cytotoxicity,” Advances in Polymer Science, Jul. 1998, pp. 1-51, 136.
Rao, B. et al., “Use of chitosan as a biomaterial: Studies on its safety and hemostatic potential,” J. Biomed. Mater. Res., Jan. 1997, pp. 21-28, 34.
Rosen, M. et al., “Laparoscopic component separation in the single-stage treatment of infected abdominal wall prosthetic removal,” Hernia, 2007, pp. 435-440, 11, published online Jul. 2007.
Scheidbach, H. et al., “In vivo studies comparing the biocompatibility of various polypropylene meshes and their handling properties during endoscopic total extraperitoneal (TEP) patchplasty: An experimental study in pigs,” Surg. Endosc., Feb. 2004, pp. 211-220,18(2).
Strand, S. et al., “Screening of Chitosans and Conditions for Bacterial Flocculation,” Biomacromolecules, Mar. 2001, 126-133, 2.
Varum, K. et al., “In vitro degradation rates of partially N-acetylated chitosans in human serum,” Carbohydrate Research, Mar. 1997, pp. 99-101, 299.
Welty, G. et al., “Functional impairment and complaints following incisional hernia repair with different polypropylene meshes,” Hernia, Aug. 2001; pp. 142-147, 5.
Zvyagintseva,, T. et al., “Inhibition of complement activation by water-soluble polysaccharides of some far-eastern brown seaweeds,” Comparative Biochem and Physiol, Jul. 2000, pp. 209-215,126(3).
Decision of Rejection issued in Chinese Application No. 201610439577.1 dated Jan. 28, 2021, with English Translation.
Related Publications (1)
Number Date Country
20200246124 A1 Aug 2020 US
Divisions (1)
Number Date Country
Parent 15169829 Jun 2016 US
Child 16839095 US